Cormorant Asset Management, LP bought $4.0M of DRUG
owner at BRIGHT MINDS BIOSCIENCES INC.. 184,331 shares at an average of $21.70, traded Nov 4, 2024, filed Nov 6, 2024.
Score components
- +12Role10% owner
- +25Trade size$4.0M at market
- +6Relative to holdingsHoldings up 21%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -30.9%, 3m -31.0%, 6m -46.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000929638-24-003752, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 4, 2024 | POpen-market purchase Common Sharesindirect: See Footnote | +184,331 | $21.70 | $4.0M | 1,059,331 | Nov 6, 2024 |
Related signals
Other insiders at BRIGHT MINDS BIOSCIENCES INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | DRUGsell BRIGHT MINDS BIOSCIENCES INC. | Cormorant Asset Management, LP other | $9.8M 109,331 shares | -10% | |
| 42Moderate | DRUGbuy BRIGHT MINDS BIOSCIENCES INC. | Cormorant Asset Management, LP owner | $3.2M 422,591 shares | +93% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.